SI2601949T1 - Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in sekretagog inzulina - Google Patents

Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in sekretagog inzulina

Info

Publication number
SI2601949T1
SI2601949T1 SI201030784T SI201030784T SI2601949T1 SI 2601949 T1 SI2601949 T1 SI 2601949T1 SI 201030784 T SI201030784 T SI 201030784T SI 201030784 T SI201030784 T SI 201030784T SI 2601949 T1 SI2601949 T1 SI 2601949T1
Authority
SI
Slovenia
Prior art keywords
methylphenylć
ethoxybenzyl
glucitol
anhydro
thio
Prior art date
Application number
SI201030784T
Other languages
English (en)
Slovenian (sl)
Inventor
Teisuke Takahashi
Saeko Uchida
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Publication of SI2601949T1 publication Critical patent/SI2601949T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201030784T 2009-04-16 2010-04-16 Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in sekretagog inzulina SI2601949T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16
EP13157571.4A EP2601949B1 (en) 2009-04-16 2010-04-16 Pharmaceutical compositions with (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol and an insulin secretagogue.

Publications (1)

Publication Number Publication Date
SI2601949T1 true SI2601949T1 (sl) 2014-12-31

Family

ID=42982643

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201030784T SI2601949T1 (sl) 2009-04-16 2010-04-16 Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in sekretagog inzulina
SI201030365T SI2419097T1 (sl) 2009-04-16 2010-04-16 Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in metformin in njegove uporabe pri zdravljenju diabetesa

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201030365T SI2419097T1 (sl) 2009-04-16 2010-04-16 Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in metformin in njegove uporabe pri zdravljenju diabetesa

Country Status (30)

Country Link
US (1) US20120040898A1 (https=)
EP (3) EP2419097B1 (https=)
JP (4) JP5077786B2 (https=)
KR (2) KR20120016051A (https=)
CN (7) CN102395364A (https=)
AR (1) AR076317A1 (https=)
AU (1) AU2010237748B2 (https=)
BR (1) BRPI1012539A2 (https=)
CA (1) CA2755392A1 (https=)
CY (2) CY1114703T1 (https=)
DK (2) DK2601949T3 (https=)
ES (2) ES2523408T3 (https=)
HK (6) HK1217301A1 (https=)
HR (2) HRP20131120T1 (https=)
ME (2) ME02015B (https=)
MX (1) MX2011010901A (https=)
MY (3) MY183793A (https=)
NZ (4) NZ606888A (https=)
PH (3) PH12015500235A1 (https=)
PL (2) PL2601949T3 (https=)
PT (2) PT2601949E (https=)
RS (2) RS53056B (https=)
RU (2) RU2532330C2 (https=)
SG (6) SG2014015093A (https=)
SI (2) SI2601949T1 (https=)
SM (1) SMT201500015B (https=)
TW (3) TW201103534A (https=)
UA (2) UA111742C2 (https=)
WO (1) WO2010119990A1 (https=)
ZA (1) ZA201106727B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AP2011005795A0 (en) 2009-02-13 2011-08-31 Boehringer Ingelheim Int SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia.
JP5758900B2 (ja) 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1202458A1 (en) 2012-05-17 2015-10-02 Vtv治疗有限责任公司 Glucokinase activator compositions for the treatment of diabetes
US9320727B2 (en) * 2012-08-30 2016-04-26 Taisho Pharmaceutical Co., Ltd Combinations of SGLT 2 inhibitors and antihypertensive drugs
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
FI4000608T3 (fi) 2013-04-18 2026-01-21 Boehringer Ingelheim Int Farmaseuttinen koostumus, menetelmä hoitamiseksi ja sen käyttöjä
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
JP6467583B2 (ja) * 2015-02-27 2019-02-13 ジ アサン ファウンデーション Ｄｐｐ−４の抑制剤を含む弁膜石灰化の予防または治療用の組成物
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
BR112019005930A2 (pt) 2016-10-19 2019-06-11 Boehringer Ingelheim Int combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas
KR20250097990A (ko) 2016-11-10 2025-06-30 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
US11439689B2 (en) * 2016-11-14 2022-09-13 Kaohsiung Medical University Method for detecting whether glucose metabolism is abnormal, and prevention and treatment therefor
US20210113561A1 (en) 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12213970B2 (en) 2018-10-29 2025-02-04 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
DK3873600T5 (da) 2018-10-29 2024-03-18 Boehringer Ingelheim Int Pyridinylsulfonamidderivater, farmaceutiske sammensætninger og anvendelser deraf
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
JP2003520759A (ja) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
WO2002083066A2 (en) * 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
RU2434862C2 (ru) * 2006-06-29 2011-11-27 Тайсо Фармасьютикал Ко., Лтд. С-фенил-1-тиоглюцитолы
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
CA2656847A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
AU2007316613B2 (en) * 2006-11-09 2013-11-28 Boehringer Ingelheim International Gmbh Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
AU2007332476A1 (en) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-phenyl 1-thio-D-glucitol derivative
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20090603A1 (es) 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv

Also Published As

Publication number Publication date
EP2601949A2 (en) 2013-06-12
JP5910711B2 (ja) 2016-04-27
NZ606888A (en) 2014-07-25
SG175154A1 (en) 2011-11-28
BRPI1012539A2 (pt) 2016-03-29
JP6066144B2 (ja) 2017-01-25
JP2013006854A (ja) 2013-01-10
EP2601949B1 (en) 2014-10-29
EP2601949A3 (en) 2013-09-18
HK1217301A1 (zh) 2017-01-06
MY183793A (en) 2021-03-16
CY1114703T1 (el) 2016-10-05
CN102395364A (zh) 2012-03-28
EP2419097A1 (en) 2012-02-22
PH12019500961A1 (en) 2020-08-03
CN105434430A (zh) 2016-03-30
UA111742C2 (uk) 2016-06-10
RU2011146335A (ru) 2013-05-27
SG2014012553A (en) 2014-05-29
CN105477639A (zh) 2016-04-13
PT2601949E (pt) 2014-11-12
PH12015500235B1 (en) 2015-12-02
ME01555B (me) 2014-04-20
KR20120016051A (ko) 2012-02-22
SI2419097T1 (sl) 2014-01-31
CN105343060A (zh) 2016-02-24
AU2010237748A1 (en) 2011-10-20
ES2523408T3 (es) 2014-11-25
TW201622720A (zh) 2016-07-01
JP2012524710A (ja) 2012-10-18
RS53761B1 (sr) 2015-06-30
PL2601949T3 (pl) 2015-04-30
ES2431300T3 (es) 2013-11-25
SG2014014807A (en) 2014-05-29
CY1115907T1 (el) 2017-01-25
RU2014121260A (ru) 2015-12-10
EP2829271A2 (en) 2015-01-28
EP2829271A3 (en) 2015-05-27
SMT201500015B (it) 2015-03-05
PH12015500235A1 (en) 2015-12-02
JP5077786B2 (ja) 2012-11-21
TW201500043A (zh) 2015-01-01
RU2532330C2 (ru) 2014-11-10
CN105343871A (zh) 2016-02-24
CA2755392A1 (en) 2010-10-21
PL2419097T3 (pl) 2014-02-28
NZ595314A (en) 2013-03-28
SG2014015093A (en) 2014-04-28
PH12019500961B1 (en) 2020-08-03
AU2010237748B2 (en) 2014-10-30
HRP20131120T1 (hr) 2013-12-20
CN105343059A (zh) 2016-02-24
EP2419097B1 (en) 2013-09-25
JP5660094B2 (ja) 2015-01-28
HK1217435A1 (zh) 2017-01-13
NZ623838A (en) 2015-09-25
UA105216C2 (en) 2014-04-25
PH12019500959B1 (en) 2020-06-29
DK2419097T3 (da) 2013-10-28
RS53056B (sr) 2014-04-30
KR20150046382A (ko) 2015-04-29
HK1217302A1 (zh) 2017-01-06
SG2014012462A (en) 2014-05-29
MY156679A (en) 2016-03-15
TW201103534A (en) 2011-02-01
HK1217434A1 (zh) 2017-01-13
CN105343880A (zh) 2016-02-24
US20120040898A1 (en) 2012-02-16
WO2010119990A1 (en) 2010-10-21
JP2015063543A (ja) 2015-04-09
HK1218881A1 (zh) 2017-03-17
DK2601949T3 (da) 2015-01-05
ZA201106727B (en) 2012-11-28
AR076317A1 (es) 2011-06-01
JP2016104775A (ja) 2016-06-09
NZ710575A (en) 2016-06-24
ME02015B (me) 2015-05-20
PH12019500959A1 (en) 2020-06-29
MY182720A (en) 2021-02-03
MX2011010901A (es) 2011-11-01
HRP20141080T1 (hr) 2015-01-02
HK1218871A1 (zh) 2017-03-17
PT2419097E (pt) 2013-10-03
EP2419097A4 (en) 2012-09-05
SG2014012405A (en) 2014-05-29

Similar Documents

Publication Publication Date Title
SI2601949T1 (sl) Farmacevtski sestavek, ki vsebuje (1S)-1,5-anhidro-1-(5-(4-etoksibenzil)-2-metoksi-4-metilfenil)-1-tio-d- glukitol in sekretagog inzulina
HUS2400029I1 (hu) Proteáz-stabilizált, acilált inzulin-analógok
HUE038147T2 (hu) GLP-1 agonistát, inzulint és metionint tartalmazó gyógyászati készítmény
IL256921A (en) Pyrazolopyrimidines, pharmaceutical preparations containing them and their use
AP2011005821A0 (en) Processing biomas.
EP2499195A4 (en) Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions
IL220509A (en) Compressed pyridinylpyrolidone, a pharmaceutical preparation and combination
IL216254A (en) Compounds, pharmaceutical compositions and their uses
BRPI1010772A2 (pt) composto,e, composição farmacêutica.
IL220283A0 (en) 4-oxo-ih-quinoline-3- carboxamides, compositions comprising the same and uses thereof
IL221952A (en) Annotations 2, 3-Dihydro-1h - Indene-1-Il-7,2- Diazaspiro [5.3] Noonan and Pharmaceuticals Containing Them
ZA201109323B (en) Adapting pushed content delivery based on predictiveness
ZA201108942B (en) Preparation comprising insulin, nicotinamide and an amino acid
AP2012006072A0 (en) Heterocyclic sulfonamides, uses and pharmaceuticalcompositions thereof.
IL220284A0 (en) Insulin analogues with chlorinated amino acids, compositions comprising the same and uses thereof
EP2455123A4 (en) Piston for syringe having very small capacity, and plunger having the piston mounted thereto
IL213997A0 (en) Heteroatom- containing cyclic compounds, compositions comprising the same and uses thereof
GR1006971B (en) Capsule, filled with a medicine, in particular an inhalable medicine.
PL2579928T3 (pl) Zespół napędowy, komponent napędu i urządzenie do podawania leku
IL222137A (en) Extensive use protection device, intended in particular for syringes and the like
AP2011005697A0 (en) The 1-butyl-2-hydroxyaralkyl piperazine derivatives and the uses as anti-depression medicine thereof.
AP2011006033A0 (en) Simalikalactone E and use thereof as a medicament.
蒋涵毅 CAVDY
Zhao JUAN ER, FANG CAO BU
IL214415A0 (en) Peptides, pharmaceutical compositions comprising same and uses thereof